게놈 바이오마커 시장 : 유형별, 적응 질환별, 검증별, 최종사용자별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

REPORT HIGHLIGHT

Genomic Biomarker Market size was valued at USD 7,684.2 Million in 2023, expanding at a CAGR of 18.20% from 2024 to 2032.

Genomic biomarkers are characteristics of DNA and RNA that are used to characterize diseases, choose treatments, and provide diagnostic information. Genomic biomarkers reflect pathological and physiological processes, as well as the reaction of the organism to treatment. One gene, a collection of genes, or the entire genome can have molecular alterations discovered by genomic biomarker testing. There may or may not be substantial supporting evidence for a connection between a genetic biomarker and the risk of contracting a disease. The clinical validity and usefulness of genomic biomarkers are influenced by two factors: genetic epidemiology data and functional laboratory assessments.

Genomic Biomarker Market- Market Dynamics

Growing Cancer Prevalence to Propel Market Growth

The market demand for genomics biomarkers is expected to increase due to the rising prevalence of various cancers, including lung, prostate, ovarian, and breast cancer. Targeting organ systems and diseases is the goal of biomarkers in human health. In particular, biomarkers are becoming more and more common in medical procedures that lead to therapy, critical care, and disease-based diagnosis. There is a growing need for genetic biomarkers worldwide in order to improve the detection and management of chronic illnesses, including cancer and cardiovascular disease. This leads to an increase in the market's demand for genomics biomarkers during the projected term.

Genomic Biomarker Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 18.20% over the forecast period (2024-2032)

Based on type segmentation, the predictive biomarkers category was predicted to show maximum market share in the year 2023

Based on disease indication segmentation, the oncology category was the leading type in 2023

Based on end user segmentation, the diagnostic category was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Genomic Biomarker Market- Segmentation Analysis:

The Global Genomic Biomarker Market is segmented on the basis of Type, Disease Indication, Validation, End User, and Region.

The market is divided into two categories based on type: Predictive Biomarkers and Prognostic Biomarkers. The predictive biomarkers category dominates the market. The reason the segment benefits is that predictive biomarkers are pretreatment or baseline data that indicate a patient's likelihood of benefiting or not from a particular treatment. When creating a particular therapeutic drug, a predictive biomarker is often selected as a companion biomarker. A common example in oncology is a biomarker that might be used to forecast when to administer trastuzumab (Herceptin) if it can identify the overexpression of the growth factor protein Her-2, which gives rise to cell proliferation in breast cancer cells. For patients with breast cancer, this medication blocks the actions of Her-2. Thus, the need for predictive biomarkers has grown as a result. Given the aforementioned claims, it can be inferred that over the forecast period, the market segment will have the greatest market share.

The market is divided into the following categories based on disease indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, and Others. The oncology category dominates the market and is likely to maintain its dominance during the forecast period. The expanding number of cancer patients worldwide and the increasing technological breakthroughs in biomarker approaches are responsible for the significant stake. Recent years have seen a number of possible uses for genomic biomarkers in oncology, including risk assessment, predictive determination, screening for differential diagnoses, tracking the course of cancer, and therapy response prediction. As per the World Health Organization (WHO), cancer ranks as the second most common cause of death worldwide, taking into consideration 70% of fatalities in low- and middle-income nations. Additionally, according to WHO estimates, there were 9.6 million cancer deaths and 18.1 million new cases of cancer reported worldwide in 2018.

Genomic Biomarker Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Over the course of the forecast period, North America is anticipated to hold the greatest share of the global market for genomic biomarker. The increasing incidence of chronic illnesses brought on by the region's shifting dietary and lifestyle patterns will ensure its domination. The market for genomics biomarkers grew as a result of the pharmaceutical industry's increased use of technology. The genomic biomarker market is expected to rise as a result of increased research and development initiatives being implemented in nations like the United States, Canada, etc.

In addition, the genomic biomarker market is anticipated to expand at the fastest rate in the world during the projected period in Asia Pacific. The countries that are anticipated to have contributed the most to the market's expansion in the area are China, Japan, South Korea, and India. The significant sums of money that both public and private organizations have invested in the advancement of the pharmaceutical sector support the expansion of the Asia Pacific market. The market's expansion in Asia Pacific is anticipated to be fueled by the growing emphasis on various genetic testing initiatives and research related to the advancement of the healthcare sector.

Genomic Biomarker Market- Competitive Landscape:

Key players in the Genomic Biomarkers market include, Thermo Fisher Scientific (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Myriad Genetics, Inc (U.S.), Eurofins Scientific (Luxembourg), and QIAGEN (Germany), among others. One or more of the growth tactics highlighted is mergers and acquisitions; other strategies include trends and analysis regarding strategic collaboration among partners, mutual agreements, and partnerships. To increase their geographic presence, the major firms are implementing cutting-edge strategies for new product releases.

Recent Developments:

May 2023: The UK MHRA and Genomics England jointly stated that they have formed a joint venture to develop cutting-edge resources to comprehend how a person's genetic composition affects the safety of medications.

May 2023: The announcement was made by Kyoto University, Fujistsu, and Chordia Therapeutics regarding their strategic partnership to begin an AI trial aimed at identifying biomarkers for novel cancer treatments. These findings have led to the collaboration's goal of developing novel cancer therapies that are tailored to each patient.

October 2022: Launching its first commercial product, Biofidelity of North Carolina said that it is funding $23 million to maintain its ASPYRE-Lung diagnostic assay for lung cancer.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GENOMIC BIOMARKER MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Thermo Fisher Scientific (U.S.)

F. Hoffmann-La Roche Ltd (Switzerland)

Eurofins Scientific (Luxembourg)

FOUNDATION MEDICINE, INC. (U.S.)

QIAGEN (Germany)

Myriad Genetics, Inc (U.S.)

Bio-Rad Laboratories, Inc. (U.S.)

MedGenome (India)

Sema4 (U.S.)

GENOME LIFE SCIENCES (India)

Almac Group (U.K.)

Creative Diagnostics (U.S.)

Quanterix (U.S.)

Others

GLOBAL GENOMIC BIOMARKER MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

• Predictive Biomarkers
• Prognostic Biomarkers

GLOBAL GENOMIC BIOMARKER MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032

• Oncology
• Cardiovascular Diseases
• Neurological Diseases
• Renal Disorders
• Others

GLOBAL GENOMIC BIOMARKER MARKET, BY VALIDATION- MARKET ANALYSIS, 2019 - 2032

• Analytical Validation
• Clinical Validation
• Clinical Utility

GLOBAL GENOMIC BIOMARKER MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

• Diagnostic
• Research Laboratories
• Hospitals
• Others

GLOBAL GENOMIC BIOMARKER MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Genomic Biomarker Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Genomic Biomarker Market Snippet by Type
  • 2.1.2. Genomic Biomarker Market Snippet by Disease Indication
  • 2.1.3. Genomic Biomarker Market Snippet by Validation
  • 2.1.4. Genomic Biomarker Market Snippet by End User
  • 2.1.5. Genomic Biomarker Market Snippet by Country
  • 2.1.6. Genomic Biomarker Market Snippet by Region
• 2.2. Competitive Insights

3. Genomic Biomarker Key Market Trends

• 3.1. Genomic Biomarker Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Genomic Biomarker Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Genomic Biomarker Market Opportunities
• 3.4. Genomic Biomarker Market Future Trends

4. Genomic Biomarker Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Genomic Biomarker Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Genomic Biomarker Market Landscape

• 6.1. Genomic Biomarker Market Share Analysis, 2023
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Genomic Biomarker Market - By Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
  • 7.1.2. Predictive Biomarkers
  • 7.1.3. Prognostic Biomarkers

8. Genomic Biomarker Market - By Disease Indication

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Disease Indication, 2023 & 2032 (%)
  • 8.1.2. Oncology
  • 8.1.3. Cardiovascular Diseases
  • 8.1.4. Neurological Diseases
  • 8.1.5. Renal Disorders
  • 8.1.6. Others

9. Genomic Biomarker Market - By Validation

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Validation, 2023 & 2032 (%)
  • 9.1.2. Analytical Validation
  • 9.1.3. Clinical Validation
  • 9.1.4. Clinical Utility

10. Genomic Biomarker Market - By End User

• 10.1. Overview
  • 10.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
  • 10.1.2. Diagnostic
  • 10.1.3. Research Laboratories
  • 10.1.4. Hospitals
  • 10.1.5. Others

11. Genomic Biomarker Market- By Geography

• 11.1. Introduction
  • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
• 11.2. North America
  • 11.2.1. Overview
  • 11.2.2. Genomic Biomarker Key Manufacturers in North America
  • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 11.2.5. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  • 11.2.6. North America Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
  • 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.2.8. U.S.
    • 11.2.8.1. Overview
    • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.2.8.4. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.2.8.5. U.S. Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.2.9. Canada
    • 11.2.9.1. Overview
    • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.2.9.4. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.2.9.5. Canada Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 11.3. Europe
  • 11.3.1. Overview
  • 11.3.2. Genomic Biomarker Key Manufacturers in Europe
  • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 11.3.5. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  • 11.3.6. Europe Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
  • 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3.8. Germany
    • 11.3.8.1. Overview
    • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.8.4. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.3.8.5. Germany Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3.9. Italy
    • 11.3.9.1. Overview
    • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.9.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.9.4. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.3.9.5. Italy Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.3.9.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3.10. United Kingdom
    • 11.3.10.1. Overview
    • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.10.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.10.4. United Kingdom Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.3.10.5. United Kingdom Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3.11. France
    • 11.3.11.1. Overview
    • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.11.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.11.4. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.3.11.5. France Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.3.11.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3.12. Russia
    • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.12.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.12.3. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.3.12.4. Russia Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.3.12.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3.13. Netherlands
    • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.13.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.13.3. Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.3.13.4. Netherlands Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3.14. Sweden
    • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.14.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.14.3. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.3.14.4. Sweden Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.3.14.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3.15. Poland
    • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.15.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.15.3. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.3.15.4. Poland Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3.16. Rest of Europe
    • 11.3.16.1. Overview
    • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 11.4. Asia Pacific (APAC)
  • 11.4.1. Overview
  • 11.4.2. Genomic Biomarker Key Manufacturers in Asia Pacific
  • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 11.4.5. Asia Pacific Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  • 11.4.6. Asia Pacific Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
  • 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4.8. India
    • 11.4.8.1. Overview
    • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.8.4. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.4.8.5. India Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.4.8.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4.9. China
    • 11.4.9.1. Overview
    • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.9.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.9.4. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.4.9.5. China Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.4.9.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4.10. Japan
    • 11.4.10.1. Overview
    • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.10.4. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.4.10.5. Japan Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4.11. South Korea
    • 11.4.11.1. Overview
    • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.11.4. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.4.11.5. South Korea Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4.12. Australia
    • 11.4.12.1. Overview
    • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.12.4. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.4.12.5. Australia Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4.13. Thailand
    • 11.4.13.1. Overview
    • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.13.4. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.4.13.5. Thailand Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.4.13.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4.14. Indonesia
    • 11.4.14.1. Overview
    • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.14.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.14.4. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.4.14.5. Indonesia Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4.15. Philippines
    • 11.4.15.1. Overview
    • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.15.4. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.4.15.5. Philippines Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4.16. Rest of APAC
    • 11.4.16.1. Overview
    • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.16.4. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.4.16.5. Rest of APAC Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 11.5. Latin America
  • 11.5.1. Overview
  • 11.5.2. Genomic Biomarker Key Manufacturers in Latin America
  • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 11.5.5. Latin America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  • 11.5.6. Latin America Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
  • 11.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5.8. Brazil
    • 11.5.8.1. Overview
    • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.8.4. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.5.8.5. Brazil Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5.9. Mexico
    • 11.5.9.1. Overview
    • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.9.4. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.5.9.5. Mexico Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5.10. Argentina
    • 11.5.10.1. Overview
    • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.10.4. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.5.10.5. Argentina Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5.11. Colombia
    • 11.5.11.1. Overview
    • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.11.4. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.5.11.5. Colombia Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5.12. Rest of LATAM
    • 11.5.12.1. Overview
    • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 11.6. Middle East and Africa
  • 11.6.1. Overview
  • 11.6.2. Genomic Biomarker Key Manufacturers in Middle East and Africa
  • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 11.6.5. Middle East and Africa Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  • 11.6.6. Middle East and Africa Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
  • 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6.8. Saudi Arabia
    • 11.6.8.1. Overview
    • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6.9. United Arab Emirates
    • 11.6.9.1. Overview
    • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6.10. Israel
    • 11.6.10.1. Overview
    • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.10.4. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.6.10.5. Israel Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6.11. Turkey
    • 11.6.11.1. Overview
    • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.11.4. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.6.11.5. Turkey Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6.12. Algeria
    • 11.6.12.1. Overview
    • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.12.4. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.6.12.5. Algeria Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6.13. Egypt
    • 11.6.13.1. Overview
    • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.13.4. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.6.13.5. Egypt Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6.14. Rest of MEA
    • 11.6.14.1. Overview
    • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.14.4. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.6.14.5. Rest of MEA Market Size and Forecast, By Validation, 2019 - 2032 (US$ Million)
    • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Genomic Biomarker Industry

• 12.1. Competitive Dashboard
• 12.2. Company Profiles
  • 12.2.1. Thermo Fisher Scientific (U.S.)
  • 12.2.2. F. Hoffmann-La Roche Ltd (Switzerland)
  • 12.2.3. Eurofins Scientific (Luxembourg)
  • 12.2.4. FOUNDATION MEDICINE, INC. (U.S.)
  • 12.2.5. QIAGEN (Germany)
  • 12.2.6. Myriad Genetics, Inc (U.S.)
  • 12.2.7. Bio-Rad Laboratories, Inc. (U.S.)
  • 12.2.8. MedGenome (India)
  • 12.2.9. Sema4 (U.S.)
  • 12.2.10. GENOME LIFE SCIENCES (India)
  • 12.2.11. Almac Group (U.K.)
  • 12.2.12. Creative Diagnostics (U.S.)
  • 12.2.13. Quanterix (U.S.)
  • 12.2.14. Others

13. 360 Degree Analyst View

14. Appendix

• 14.1. Research Methodology
• 14.2. References
• 14.3. Abbreviations
• 14.4. Disclaimer
• 14.5. Contact Us